SynteractHCR, a full-service, international CRO, and The GOG Foundation, a nonprofit focused on gynecologic oncology research, have signed a Teaming Agreement to work together on gynecologic oncology clinical studies. The relationship will offer a streamlined process for drug development companies to improve the timeliness of determining clinical research studies as well as facilitate high quality, rapid trial execution. The relationship is reciprocal and has a three-year term.
The GOG Foundation (GOG) works with biopharmaceutical drug developers that are researching innovative therapies in gynecologic cancer indications. More than 300 investigational institutions are in its network in Japan, Korea, Australia and the U.S., including the vast majority of the U.S. gynecologic oncology community. GOG helps biopharma developers with clinical trial protocol development, feasibility, budgeting and other aspects and was looking for a clinical trial services partner.
GOG screened several large and small CROs before selecting SynteractHCR as the best cultural and operational fit. GOG will recommend SynteractHCR, which has offices in the U.S., Western and Eastern Europe, as its preferred CRO to assist its drug developer clients.
SynteractHCR will support GOG-related sponsors with any/all components of clinical trials, including clinical trial services, data management, medical and regulatory affairs, pharmacovigilance and biostatistics, as well as customized services, to meet their needs. It will also recommend GOG to sponsors it is working with or who approach it for an RFP, giving them instant access to the GOG network of physicians and institutions to simplify the process of finding patients and investigators.
"GOG views this Teaming Agreement as a 'win-win' for both of our organizations and for the industry. Together, our organizations will give sponsors increased confidence with our extensive experience and an integrated approach to their trials. I am personally excited about this opportunity to work with SynteractHCR on our industry sponsored clinical trials,” said Dr. Larry J. Copeland, GOG president-elect.
SynteractHCR is a full-service, international contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and in 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.
Wendel Barr, CEO for SynteractHCR, concurs with Dr. Copeland’s assessment. “By working with The GOG Foundation, we will have this network of 300 sites we can go to right away. And this puts both the drug sponsors and the patients at an advantage immediately. Having successfully provided fair market value services to GOG on previous GOG partner studies, we know we work together well and will make a great team.”